Northern Light Venture Capital, established in 2005, is a China-focused venture capital firm headquartered in Menlo Park, California. Led by a team of experienced local Chinese and "returnee" executives, the firm manages multiple funds totaling approximately US$1.5 billion. Northern Light invests in early and growth-stage opportunities across information technology, new media, TMT, clean technologies, consumer services, and healthcare sectors. Notable portfolio companies include Meituan.com and Kaixin001.com. The firm targets innovative and disruptive technologies that leverage China's resources to build global enterprises.
Suite 1720, 17/F Hutchison House, 10 Harcourt Road, Central, Hong Kong
Feng Deng
Founding Managing Director
Freeman Ding
Executive Director
Jeffrey Lee
Co-Founder and Director
Lei Yang
Partner
Lixin Li
Managing Director
Lu Lin
Executive Director
Simon Sun
Venture Partner
Zhi Tan
Venture Partner
Tony Wu
Partner
Ben Yan
Executive Director
Fiona Yu
Partner
Johnny Zhang
Associate
Zhang Peng
Investment Analyst
439 past transactions
VOC AI
Venture Round in 2025
VOC AI offers AI tools for ecommerce insights and customer service solutions.
AscentStream
Angel Round in 2025
AscentStream is a software development company that provides cloud messaging software and stream processing solutions.
Shengrun New Materials
Seed Round in 2025
Shengrun New Materials is an aerogel material and system solution service provider integrating advanced material process research and development, product application development, advanced production line design, and mature system solutions.
weshare
Seed Round in 2024
Weshare is an IT company that specializes in big data, cloud computing, and artificial intelligence services. Weshare pursue the innovative and harmonious development of people, things, and the business ecosystem which creates maximum value with the trend. They are committed to providing scientific and technological services worldwide through continuous exploration and technologies.
TULIU.com
Series C in 2024
TULIU.com is an online platform dedicated to facilitating land transfers in China. It aggregates essential information such as land area, pricing, and development trends to create a standardized evaluation system. The company offers farmers complimentary land value assessment services, helping them understand the worth of their properties. In addition to its evaluation services, TULIU.com provides comprehensive information about real estate, including details on available properties for sale or lease, insights into land brokers, land indexes, and updates on relevant laws and policies governing land transfer and leasing. This holistic approach enables users to make informed decisions regarding their real estate needs.
RootData
Seed Round in 2024
RootData operates as a Web3 asset data platform that pioneers in encapsulating both on-chain and off-chain data of Web3 assets.
Wanglitong
Seed Round in 2024
Wanglitong manufactures lithium battery auxiliary materials. It currently specializes on lithium battery films and membrane materials. Its current product lines include brown high-temperature tape, milky white OPP tape, and TPU expansion tape, all of which have reached mass production.
Coordinate System Intelligence
Seed Round in 2024
Coordinate System Intelligence is a provider of automotive brake-by-wire system solutions. It focuses on providing core technology solutions.
Infinigence
Series A in 2023
Infinigence is dedicated to providing AGI computing power solutions based on its large model energy efficiency optimization tools, with the goal of resolving the challenge of efficient and unified deployment of large model algorithms to large computing power chips.
Sanegene Bio
Series A in 2023
Sanegene Bio is engaged in the development of RNA interference (RNAi) therapeutics aimed at addressing unmet clinical needs across various therapeutic areas. The company’s RNAi drug discovery platform focuses on effectively knocking down disease-causing genes, utilizing advanced RNA technology to ensure specific delivery of multiple RNA drugs. This innovative approach allows for targeted treatment of patients suffering from a range of conditions, including cardiovascular and metabolic diseases, immunology-related diseases, infectious diseases, and disorders affecting the central nervous system and eyes. Through its comprehensive RNAi portfolio, Sanegene Bio seeks to provide effective therapeutic solutions for challenging health issues.
Zhonghui Laser
Series A in 2023
Zhonghui Laser is an emerging technology company dedicated to the development and manufacture of advanced lasers.
Flytech
Angel Round in 2023
Flytech specializes in crystal materials and related components for magneto-optical-electrical integrated signal processing.
Chaoying Pharmaceutical
Angel Round in 2023
Chaoying Pharmaceutical offers ultrasonic contrast agent preparation technologies along with the installation of sterile production lines which can be used for real-time monitoring and evaluation of various surgeries.
Kangpu Biopharmaceuticals
Series B in 2023
Kangpu Biopharmaceuticals is a clinical-stage company dedicated to the discovery and development of small molecule drugs aimed at treating cancer, autoimmune diseases, and inflammatory disorders. The company leverages proprietary technologies that focus on the modulation of ubiquitin-protein interactions to create innovative medical treatments. Additionally, Kangpu employs a drug discovery platform known as X-Synergy®, which enhances its capabilities in developing targeted therapies. By utilizing novel approaches such as targeted protein ubiquitination and degradation, Kangpu aims to deliver effective medical solutions that improve patient health outcomes.
Moge Microflow
Seed Round in 2023
Moge Microflow is a manufacturer of equipment for microreactors. It provides continuous flow production technologies and equipment for nanomaterials, pharmaceutical intermediates, and fine chemicals, as well as standardized high-end microreactor equipment.
Aegis
Seed Round in 2023
Aegis is a blockchain security company.
Kanova
Series B in 2023
Kanova is a biopharmaceutical company dedicated to the development of therapeutic antibodies and innovative combination therapies targeting immuno-oncology and autoimmune diseases. The company offers a biomedical technology service platform that supports pharmaceutical research and production in biotechnology. It specializes in antibody-based drugs that enhance immune system function, along with providing technical consultation and drug quality inspection services. By focusing on these areas, Kanova aims to help clients improve drug quality and advance the discovery of new biomedicine efficiently.
Next Generation Gene Therapeutics
Series B in 2023
Next Generation Gene Therapeutics is a healthcare company that engages in the research and development of gene therapy. Its unique propriety technology of "one target and two bullets" can provide effective treatment for a variety of genetic diseases that currently have few therapeutic methods in the world. NGGT was founded in March 2020 by senior scientists and entrepreneurs in the field of gene therapy. It is committed to becoming the world's leading gene therapy company with international influence. The company has successful experience in the whole industry chain, concerning the early development of gene therapy products, the large-scale production of viral vectors, the construction of quality standards, international multi-center clinical research, and the application for the marketing of gene therapy products.
Quick Sensing
Angel Round in 2023
Quick Sensing is a high-pressure-pressure automotive sensor developer.
ECTEK
Post in 2023
ECTEK is a developer and manufacturer specializing in electronic control hardware and software platforms. The company provides a customized and open electronic control platform designed to facilitate the integration of various power systems. Its product offerings include electronically controlled systems for diesel engines, gas engines, and pure electric power, as well as solutions for automated manual transmission (AMT), oil-electric hybrid systems, and fuel cells. Additionally, ECTEK focuses on intelligent network connections and related service systems, enabling customers to achieve seamless integration across their power systems.
Xinrui Medical
Seed Round in 2023
Xinrui Medical is a domestic enterprise that engages in the research and development of polymer valves. It focuses on new polymer valves to build a complete solution for heart valve disease. The team members have long been engaged in the research and development of polymer synthesis and polymer-related medical devices. They are all from well-known medical device companies and have complete product development experience and mature industrialization thinking.
Power Site
Series B in 2023
Power Site is a modern technology enterprise that supplies X-ray imaging core components. It mainly provides high-voltage generators (HVG), combined X-ray sources, power distribution units (PDU), and other core components overall solutions for X-ray imaging systems. The products are mainly used in high-end X-ray imaging systems such as CT, DR, mammography, C-arm, CBCT, security inspection, industrial inspection, etc. The company has an advanced and efficient manufacturing platform with an annual production capacity of 50,000 units.
Eeasy Tech
Series B in 2022
Eeasy Tech, officially known as Yizhi Electronic Technology Co., Ltd., is a system solution provider specializing in AI machine vision algorithms and SOC chip design. Founded in Zhuhai in 2016, the company operates additional offices in Beijing and Shenzhen. With a workforce of over 100 employees, many of whom are graduates from top domestic universities, the core team possesses extensive experience in SOC chip mass production. The company focuses on independent research and development of intellectual property related to AI acceleration, high-definition display, audio and video codecs, and high-speed digital-analog mixing. Its SOC chip technology is applied across various sectors, including industrial control, consumer electronics, automotive electronics, and smart home solutions. By offering services such as SOC chip design, audiovisual processing, software development, and AI solutions, Eeasy Tech supports clients in their system construction, hardware development, and market expansion efforts.
Surpath
Seed Round in 2022
Surpath is an AI-driven cloud-based platform that formulates optimal supply chain solutions based on clients' needs. The firm provides cross-border transportation to destination services, optimized logistics, and analytics solutions that solve complex problems.
HemaCell
Series A in 2022
HemaCell is a cell therapy company specializing in the in vitro regeneration of hematopoietic lineages, including blood and immune cells. Founded by experts with extensive experience in the field, the company utilizes advanced stem cell reprogramming and differentiation technologies to develop innovative solutions. HemaCell is focused on addressing the pressing demand for platelets in the treatment of various conditions, such as cancer, liver disease, critical illnesses, and hematological disorders. Additionally, the company is dedicated to creating new therapeutic drugs targeting diseases associated with platelet abnormalities, thereby offering effective treatment options for patients.
Point One
Series B in 2022
Point One is a 3D Metaverse user-generated content platform. Using simple no-code tools, users may build personalized 3D interactive content.
BUD
Series B in 2022
BUD, founded in 2019 by former Snap engineers Risa Feng and Shawn Lin, is a Singapore-based company that operates a user-generated open metaverse gaming platform. This platform connects millions of virtual worlds created by a community of approximately 9 million creators. Since its global launch in November 2021, BUD has rapidly gained popularity, ranking among the top 10 social apps in over 38 countries, including regions in North America, Southeast Asia, and South America. The platform allows users to easily customize 3D worlds through a simple drag-and-drop interface, enabling the creation and sharing of interactive experiences that range from social hangouts to competitive games. BUD has evolved into a vibrant digital social hub where users can create, play, and interact with 3D content alongside friends.
Jingwei Shida
Series A in 2022
Jingwei Shida is a medical equipment R&D and supplier, focusing on the research and development of optoelectronic medical equipment.
CSR Biotech
Seed Round in 2022
CSR Biotech is a biological research company that specializes in super-resolution imaging technologies for living cells. The company focuses on the research, development, and manufacturing of advanced imaging instruments, providing a range of services such as customized cell sample generation, high-throughput detection, and imaging studies. Additionally, CSR Biotech offers image post-processing and quantitative analysis, along with high-dimensional spatio-temporal data visualization. These services are designed to support bio researchers in discovering new disease biomarkers and innovative drug targets, thereby enhancing the capabilities of scientific exploration in the field of biotechnology.
Huahuixin Group
Series B in 2022
"Huahuixin" was established in 2017. Its core capabilities are the design, development and production of micro-nano structured optical chips and laser chips, which are in the upstream chip manufacturing link of the optoelectronics industry. There are two main business models: on the one hand, relying on high-end optoelectronic chip technology capabilities to provide joint R&D and foundry services for optoelectronic chip design companies; on the other hand, based on the team's technical capabilities in micro-nano structured optical chips and laser chips, Independent research and development, design and large-scale production of optoelectronic products.
Zhonghui Laser
Series A in 2022
Zhonghui Laser is an emerging technology company dedicated to the development and manufacture of advanced lasers.
Xinrui Medical
Angel Round in 2022
Xinrui Medical is a domestic enterprise that engages in the research and development of polymer valves. It focuses on new polymer valves to build a complete solution for heart valve disease. The team members have long been engaged in the research and development of polymer synthesis and polymer-related medical devices. They are all from well-known medical device companies and have complete product development experience and mature industrialization thinking.
Xmov Ai
Series C in 2022
Xmov is a company that specializes in developing artificial reality animation solutions, focusing on virtual human and content creation tailored for enterprise users across various Metaverse applications. The company employs advanced motion capture, animation, and artificial intelligence technologies to deliver customized interactive solutions for diverse business scenarios. Additionally, Xmov creates a comprehensive infrastructure for 3D virtual content production, providing full-stack technology and product services aimed at facilitating education, employment, and the development of virtual world platforms. Their innovative approach spans multiple sectors, including entertainment, cultural tourism, e-commerce, finance, education, healthcare, and communications, establishing a multifaceted ecological development model.
Binance.US
Seed Round in 2022
Binance.US operates as a regulated cryptocurrency exchange that offers a marketplace for buying, selling, and trading a variety of digital assets. It is recognized as a FinCEN regulated entity in the United States, ensuring compliance with relevant financial regulations. The platform is designed to promote financial confidence and enhance crypto literacy among users, providing access to innovative technology that facilitates trading with low fees and transaction costs. Binance.US aims to support the transition to a digital economy by delivering a fast, secure, and reliable trading environment for everyday users.
Nanovision
Venture Round in 2022
Nanovision Technology, based in the Zhongguancun Yongfeng high-tech industrial base with an additional subsidiary in Chengdu, specializes in high-speed and high-precision radiology imaging. The company focuses on the development of static CT, X-ray CMOS detectors, and X-ray imaging software. Notably, Nanovision created China's first self-developed CMOS flat panel detector, known as the Merak series. Its products are applicable in various sectors, including medical, industrial, and security, offering advanced technological support both domestically and internationally. With a significant research and development foundation, Nanovision is positioned as a key player in the radiation imaging industry.
Tensor Security
Seed Round in 2022
Tensor Security is a full-stack endogenous cloud-native security solution. Their solution includes automation and devsecops,safety compliance, market container security,dynamic privileged account management, and cloud host security. Their cloud-native security platform builds a trusted image security system to ensure image security throughout the entire life cycle of cloud-native applications.
Nutshell Therapeutics
Series A in 2022
Nutshell Therapeuticstein drug discovery platform, composed of a well-integrated set of computational modules and experimental tools based on a proprietary AI algorithm and deep know-how derived from biochemistry and biophysics, possesses the capability to discover a host of drug entities, including various types of protein activators and subtype/mutation-selective small molecules.
Yudao Bio
Series A in 2022
Yudo Bio provides biopharmaceutical products. It has its headquarters in Shanghai in China.
HemaCell
Seed Round in 2022
HemaCell is a cell therapy company specializing in the in vitro regeneration of hematopoietic lineages, including blood and immune cells. Founded by experts with extensive experience in the field, the company utilizes advanced stem cell reprogramming and differentiation technologies to develop innovative solutions. HemaCell is focused on addressing the pressing demand for platelets in the treatment of various conditions, such as cancer, liver disease, critical illnesses, and hematological disorders. Additionally, the company is dedicated to creating new therapeutic drugs targeting diseases associated with platelet abnormalities, thereby offering effective treatment options for patients.
Ucello Therapeutics
Series A in 2022
Ucello Therapeutics focuses on the development of allogeneic cell therapies utilizing its proprietary CAR-T cell technology platform, known as CBT-X20. The company aims to create universal CAR-T cell therapeutic drugs that address unmet clinical needs in cancer treatment. By leveraging advanced gene and cell therapy technologies, Ucello's therapies target cancer cells at the molecular level, making them accessible to patients with varying lymphocyte levels and those with a history of transplant relapse. This innovative approach allows for effective cancer gene therapies to be administered to individuals with specific pre-existing medical conditions.
Genepoint Biological Technology
Series C in 2022
Genepoint Biological Technology (China) Co., Ltd. specializes in the manufacture of devices for cryogenic biomaterial storage and handling, aimed at supporting life sciences research. Based in Shanghai, the company offers a range of products, including Automated Cryo-Bio Storage systems, Plugged Hybrid Cryo-Storage units, and LIN Vapor Freezers. These innovative solutions are designed to facilitate biotechnology research and development by enhancing the efficiency of sample storage operations. Genepoint is committed to advancing cryogenic robotic systems, enabling researchers to manage biological samples effectively and conduct experiments with greater ease.
Mindfront Health
Seed Round in 2022
Mindfront Health is a mental health company based in Shanghai, China, specializing in comprehensive diagnosis and treatment through evidence-based psychotherapy services. Established in 2020 as a brand under Luye Life Sciences Group, Mindfront Health operates a chain of psychiatric facilities across major cities, including Shanghai, Shenzhen, Guangzhou, and Xi'an. The company employs a dual approach that combines evidence-based drug treatments with non-drug interventions, aimed at addressing various mental health issues such as depression, sleep disorders, ADHD, and gaming addiction. Mindfront Health is committed to creating personalized treatment systems that cater specifically to the needs of the Chinese population, and it also offers an internet medical service platform to enhance accessibility. Through strategic collaborations with local institutions and leveraging Luye's clinical services, Mindfront Health aims to replicate its model at scale, providing holistic mental health solutions to its patients.
OUTPUT
Venture Round in 2022
OUTPUT is a creative platform for the innovation of digital experiences. It features cutting-edge digital artists, designers, and developers across the globe, initiating cross-industrial practices online and offline, updating multi-dimensional experiences generated by digital art and design, and nurturing a central hub for generative dialogues via digital experiences.
H-CHIP TECH
Venture Round in 2022
H-CHIP TECH is a high-end optoelectronic research and development company based in Tianjin, China. It focuses on the development of micro-nano optoelectronic chips for industrial clients, particularly in the realm of distributed feedback (DFB) semiconductors. The company's expertise lies in creating advanced optoelectronic chips that provide reliable technological support for the optical communication industry, catering to the growing demand for innovative solutions in this field.
CATUG Biotechnology
Venture Round in 2022
CATUG Biotechnology specializes in the development and application of advanced biomedical technologies, particularly in the fields of gene therapy and nucleic acid drugs. The company offers comprehensive contract development and manufacturing organization (CDMO) services, addressing the entire industry chain from research and development to clinical applications and industrialization. CATUG operates R&D centers and industrialization bases located in Suzhou and Wuhan, facilitating its focus on drug research and production services.
Wancheng Gene
Series A in 2021
Wancheng Gene is a single-cell gene detection platform, which is mainly used to serve the scientific research, clinical and industrial markets with a self-developed high-throughput single-cell sequencing technology platform. The existing services of Wancheng Gene include sample preparation, database sequencing, analysis, and sample processing. They can be freely combined according to customer needs, and provide peripheral services such as sample preparation training and biometric analysis.
Kind Pharmaceutical
Series B in 2021
Kind Pharmaceutical is a clinical-stage biopharmaceutical company that focuses on the discovery and development of anemia drugs. The company was founded in 2013 and is headquartered in Redwood City, California, United States.
Stellar Cyber
Series B in 2021
Stellar Cyber Inc. is a cybersecurity company based in Santa Clara, California, founded in 2015. It specializes in developing an open Extended Detection and Response (XDR) platform that enhances application and data protection for organizations. The platform integrates data from various security tools to provide comprehensive threat detection and response capabilities, automatically correlating alerts into incidents across the entire attack surface. Stellar Cyber's solutions are designed to significantly reduce enterprise risk by facilitating the early identification and remediation of cyber threats while optimizing costs and maintaining investments in existing security infrastructure. The platform also allows for seamless deployment of sensors both on-premise and in the cloud, enhancing visibility and operational efficiency for security teams.
Novlead Biotech
Series B in 2021
Novlead Biotech is a developer and manufacturer of medical devices specializing in cardiopulmonary, respiratory, and anti-infection applications. The company leverages technological innovations, particularly the medical application of nitric oxide, to address conditions such as pulmonary hypertension and infectious diseases. By focusing on these critical areas, Novlead Biotech aims to enhance treatment efficiency in hospitals and improve the quality of life for patients. Through its advancements, the company contributes to safer and healthier outcomes in healthcare.
TenaFe
Series B in 2021
TenaFe, Inc. is a technology company that specializes in the development of solid-state drive (SSD) controllers aimed at enhancing data storage solutions across various platforms, including client devices, data centers, and emerging edge applications. Founded in 2018 and based in Campbell, California, TenaFe leverages its patented technology to deliver SSDs characterized by exceptional reliability, performance, and energy efficiency. These innovations serve a diverse array of devices, from connected gadgets and personal computers to large-scale data center operations, ultimately improving storage reliability and energy consumption for its clients.
RiVAI
Series A in 2021
RiVAI Technologies specializes in the development of advanced RISC-V based CPUs and customized System-on-Chip (SoC) designs. The company focuses on delivering high-performance computing solutions for diverse applications, ranging from edge computing to data centers. Additionally, RiVAI develops artificial intelligence chips tailored for Internet of Things (IoT) applications, catering to various sectors such as wearable technology, smart homes, security systems, agriculture, and consumer electronics. By offering low-power yet high-performance core processor chips, RiVAI enables its clients to meet the growing demands of modern computing environments.
New Core Technology (Xinyunhe)
Series C in 2021
It provides mobile enterprise resource planning(ERP) systems for sales, production and storage management.
HC Scientific
Series B in 2021
HC Scientific (Chengdu) L.L.C., founded in early 2016, focuses on developing intelligent solutions within the life sciences sector. The company aims to be a trusted partner for global clients by offering innovative products, including genetic testing instruments, reagents, and software. These products are primarily used in clinical molecular diagnostics, health gene testing, and agricultural molecular breeding. HC Scientific is recognized as a national high-tech enterprise, emphasizing autonomous research and the development of intellectual property. The company participates in significant national and provincial scientific initiatives and is supported by a team of experts, including returning PhDs. Its product offerings streamline complex tasks for life science practitioners, delivering high-throughput, automated, and cost-effective genetic testing solutions while creating value for collaborative partners.
XinHeYun
Series C in 2021
New Nuclear Cloud is an industrially intelligent software service company that combines data and processes to realize the needs of manufacturing enterprises and configure services. They provide container technologies and services to meet the various needs of enterprises for data deployment.
Xiaoice
Series A in 2021
Bombax is an AI company that develops a chatbot that acts as a digital assistant with the capability to understand human conversations. Bombax allows cross-platform interactions, enabling users to enjoy the convenience of artificial intelligence. Xiaoice is designed as a teenage girl and is touted as an empathic computing framework focusing on longer back-and-forth conversations with humans instead of simply answering questions or obeying commands like most bots. Its technology covers natural language processing, computer voice, computer vision, and AI content generation.
Orient Speech Therapy
Series C in 2021
Orient Speech Therapy Center is a professional organization focused on enhancing children's speech and mental development. It specializes in providing speech and language therapy services for children with speech disorders, including those with autism. The center offers early screening, clinical diagnosis, and therapeutic interventions to support improved communication skills. To facilitate this development, Orient Speech Therapy has designed comprehensive curriculums, including the Star Curriculum, which targets children's speech, social skills, phonics, and oral muscle exercises. Through these tailored programs, the center aims to help children overcome communication challenges and foster their overall growth.
Micot
Series B in 2021
Micot is a new molecular entity drug developer for peptides, dedicated to the development of innovative drugs, multi- and protein-based innovative biopharmaceuticals, vaccines and biomolecular drug delivery systems and products, and for drug screening and biopharmaceutical research. The technology combines to provide users with Bio-Res-Deliv, a biological macromolecular respiratory drug delivery system, suitable for the treatment of cardiovascular diseases, metabolic diseases, liver diseases and the like.
Nutshell Therapeutics
Series A in 2021
Nutshell Therapeuticstein drug discovery platform, composed of a well-integrated set of computational modules and experimental tools based on a proprietary AI algorithm and deep know-how derived from biochemistry and biophysics, possesses the capability to discover a host of drug entities, including various types of protein activators and subtype/mutation-selective small molecules.
Omnisensing Photonics
Series A in 2021
OmniSensing Photonics specializes in the development and manufacturing of advanced photonics sensing solutions, focusing on high-end laser sensing technology and LiDAR products. The company offers a range of innovative products, including the DFS-2 dual fiber sensor module, POF-48 multi-channel optical sensing probe, and MV-H compact laser vibrometer sensor, which are designed for accurate vibration and displacement measurements in various scientific and industrial applications. By utilizing photonics integrated circuits and coherent communication, OmniSensing aims to transform traditional 3D technologies and cater to emerging fields such as precision manufacturing, machine vision, and autonomous driving. The company is dedicated to delivering customer-focused solutions that leverage cutting-edge photonics chip and packaging technologies.
Speedaf Express
Series A in 2021
Speedaf Logistics Limited specializes in integrated logistics and transportation services primarily between China and Africa. Founded in 2019 and headquartered in Shenzhen, China, the company offers a comprehensive range of services, including air, sea, and road transportation, as well as warehousing, packaging, and labeling. Speedaf aims to optimize logistics costs and enhance efficiency through its platform, which provides order information and online tracking services. With additional offices in Ghana, Nigeria, Kenya, and Uganda, Speedaf positions itself as a one-stop logistics service provider, delivering stable and recognized supply chain solutions to its clients in the region.
LuxCreo
Series B in 2021
LuxCreo Inc., established in 2017, specializes in 3D printed dental solutions, featuring an FDA Class II 510(k) cleared additive manufacturing platform. The company enhances productivity in dental clinics and laboratories by enabling the same-day production of dental appliances such as aligners, retainers, night guards, and splints, achieving efficiency improvements of three to ten times. LuxCreo's innovative technology not only streamlines the manufacturing process but also ensures rapid delivery and elevated patient care through increased precision and hygiene. In addition to its core dental services, LuxCreo also engages in software and electronic hardware development, further contributing to advancements in 3D printing technology and improving overall production efficiency in the manufacturing sector.
Yuanbao Insurance Research Institute
Series C in 2021
Yuanbao provides users with insurance products and services. The company's product types include medical insurance, critical illness insurance, and comprehensive accident insurance. The company are committed to providing customers with domestic insurance planning services and helping customers customize insurance plans.
Next Generation Gene Therapeutics
Series A in 2021
Next Generation Gene Therapeutics is a healthcare company that engages in the research and development of gene therapy. Its unique propriety technology of "one target and two bullets" can provide effective treatment for a variety of genetic diseases that currently have few therapeutic methods in the world. NGGT was founded in March 2020 by senior scientists and entrepreneurs in the field of gene therapy. It is committed to becoming the world's leading gene therapy company with international influence. The company has successful experience in the whole industry chain, concerning the early development of gene therapy products, the large-scale production of viral vectors, the construction of quality standards, international multi-center clinical research, and the application for the marketing of gene therapy products.
InnoStar Semiconductor
Seed Round in 2021
InnoStar Semiconductor specializes in developing and providing advanced semiconductor storage solutions, particularly focusing on resistive random access memory (ReRam) technology. This innovative approach offers high performance and low power consumption, catering to various industries including information security, Internet of Things (IoT), artificial intelligence (AI), and cloud computing. By commercializing ReRam memory chips, InnoStar aims to enhance storage capabilities and intelligent computing, setting new industry standards while addressing the growing demands for efficient data processing and storage solutions.
Brattea
Series B in 2021
Brattea is a medical device research and development company specializing in renal denervation products aimed at treating conditions such as hypertension, cancer pain, and diabetes. The company develops interventional devices, including renal artery ablation catheters and radiofrequency ablation equipment, as well as medical mapping systems. These products are designed to address a range of health issues, including refractory hypertension, obstructive sleep apnea, kidney disease, and heart failure. Brattea is committed to providing reliable medical solutions that enhance patient care and improve health outcomes.
Immune-Onc Therapeutics
Series B in 2021
Immune-Onc Therapeutics, Inc. is a clinical-stage biopharmaceutical company based in Palo Alto, California, founded in 2016. The company specializes in the discovery and development of innovative biologic therapies aimed at treating cancer. Immune-Onc Therapeutics focuses on the tumor microenvironment and immune suppressive pathways, utilizing advanced scientific insights to create novel immuno-oncology products. The company employs a targeted approach to develop first-in-class therapeutic antibodies that disarm immune suppression in tumors, thereby enhancing the immune response against cancer. Through its differentiated pipeline, Immune-Onc Therapeutics aims to provide new treatment options for cancer patients, addressing critical needs in the field of immunology and oncology.
Vivest
Seed Round in 2021
Vivest engages in R&D of emergency medical equipment.
MediTrust Health
Series B in 2021
MediTrust Health is a leading healthcare platform in China that offers a wide range of health insurance products and comprehensive medical services. The company connects pharmaceutical companies, insurers, hospitals, and patients, creating a cohesive ecosystem that benefits all stakeholders involved. By integrating high-quality medical resources with health insurance, MediTrust Health aims to deliver affordable, personalized healthcare solutions to families. In addition to its insurance offerings, the company focuses on improving the management of medical expenses and enhancing patient access to necessary services through innovative payment solutions. MediTrust Health's commitment to addressing the complexities of medical financing and providing diverse healthcare benefits positions it as a significant player in the healthcare industry.
Minayo
Seed Round in 2021
Minayo is a food company specializing in the manufacture and distribution of health supplements and functional snacks. The company aims to enhance consumer health and performance by offering products that are both nutritious and convenient. Through its focus on functional snacks and nutritional supplements, Minayo provides options that cater to health-conscious individuals seeking to improve their overall well-being.
Teon Therapeutics
Series A in 2021
Teon Therapeutics is a clinical-stage biopharmaceutical company based in Redwood, California, founded in 2018. The company is focused on developing small molecule drugs aimed at cancer immunotherapy as well as addressing cardiovascular and metabolic diseases. Teon Therapeutics specializes in creating single-target small molecules that inhibit immunosuppressive and cancer-promoting signaling pathways within the tumor microenvironment. Its lead program involves an A2BR-specific antagonist, which is set to enter Phase 1b trials. By combining metabolic and GPCR immune checkpoint inhibitors, Teon aims to enhance the efficacy of immunotherapies, thereby improving long-term outcomes for cancer patients.
Singular Medical
Series B in 2021
Singular Medical is a technology company focused on the research, development, and industrialization of cardiac rhythm management (CRM) products. The company designs and develops a comprehensive range of high-quality medical devices, including implantable cardioverter defibrillators, pacemakers, and implantable cardiac monitors. Singular Medical aims to provide reliable and professional medical equipment that addresses the needs of a large population of cardiac patients, offering solutions that span from initial detection to ongoing follow-up care.
Neurophth Therapeutics
Series B in 2021
Wuhan Neurophth Biotechnology Co., Ltd. is a pioneering ophthalmology gene drug research and development company based in Wuhan, China, established in 2008. It focuses on gene therapies for ocular genetic diseases, with a particular emphasis on Leber hereditary optic neuropathy (LHON), a condition caused by genetic mutations. Neurophth has made significant advancements in the field, completing the world's first clinical study of gene therapy for LHON in 2011, which involved nine patients and has since observed their progress over seven years. The company aims to develop effective treatments for various ophthalmic disorders, including degenerative optic nerve injuries and vascular retinopathy, thereby providing physicians with innovative therapeutic options for patients suffering from these conditions.
Orient Speech Therapy
Series C in 2021
Orient Speech Therapy Center is a professional organization focused on enhancing children's speech and mental development. It specializes in providing speech and language therapy services for children with speech disorders, including those with autism. The center offers early screening, clinical diagnosis, and therapeutic interventions to support improved communication skills. To facilitate this development, Orient Speech Therapy has designed comprehensive curriculums, including the Star Curriculum, which targets children's speech, social skills, phonics, and oral muscle exercises. Through these tailored programs, the center aims to help children overcome communication challenges and foster their overall growth.
XinHeYun
Series B in 2021
New Nuclear Cloud is an industrially intelligent software service company that combines data and processes to realize the needs of manufacturing enterprises and configure services. They provide container technologies and services to meet the various needs of enterprises for data deployment.
magAssist
Series B in 2021
Suzhou Xinqing Medical Technology Co., Ltd., founded in 2017 by Dr. Xu Bozhen, focuses on the development of in-vitro artificial heart devices aimed at assisting patients with cardiovascular illnesses. The company specializes in creating short-term to medium-term ventricular assist devices that leverage advanced fluid mechanics and magnetic suspension technology. These innovations allow the devices to be compatible with various blood types, thereby reducing the risk of incompatibility for patients. With a team of leading experts in artificial heart engineering, the company has successfully developed an artificial heart that holds independent intellectual property rights, positioning itself as a key player in the medical technology sector.
Picky
Pre Seed Round in 2021
Picky is a mobile-first community dedicated to helping consumers discover the most suitable skincare and beauty products through user reviews, educational content, and expert contributions. The platform emphasizes authenticity, education, and personalization, allowing users to engage with content focused on skincare, including K-beauty. Picky offers a Skin Type Analyzer, a quick tool that helps users identify their skin type through a series of 14 simple questions. Based on the results, users can better understand their unique skin characteristics and find products tailored to their needs. The platform boasts a regularly updated database of over 40,000 beauty products, ranging from established favorites to emerging indie K-beauty brands. Additionally, Picky connects users with healthcare professionals, facilitating appointments with optometrists, dermatologists, dentists, and plastic surgeons, streamlining access to health and beauty services.
GenFleet Therapeutics
Venture Round in 2021
GenFleet Therapeutics, based in Shanghai, China, is a biotechnology company focused on the research and development of therapeutic molecules aimed at cancer treatment. Founded in 2017, the company specializes in creating innovative molecular pharmaceuticals and antibody drugs that target various cancer systems. GenFleet's work involves developing signal transduction regulators, tumor microenvironment modulators, and transcription factors, among other therapeutic agents. The company's mission is to provide effective medical solutions that can reactivate tumor-specific immune responses and enhance the body's own immune system in combating cancer. With a commitment to advancing cancer therapies, GenFleet serves both domestic and international markets.
VesiCURE
Venture Round in 2021
VesiCURE Therapeutics is a company dedicated to the research and development of innovative exosome-based drugs. Founded in 2021 and located in Suzhou, Jiangsu, China, VesiCURE aims to advance the exosomal pharmaceutical industry by focusing on the creation and enhancement of exosomal therapies. The company's efforts are centered on harnessing extracellular vesicles to develop new drug formulations, thereby contributing to the evolution of this emerging sector in medicine.
Power Site
Venture Round in 2021
Power Site is a modern technology enterprise that supplies X-ray imaging core components. It mainly provides high-voltage generators (HVG), combined X-ray sources, power distribution units (PDU), and other core components overall solutions for X-ray imaging systems. The products are mainly used in high-end X-ray imaging systems such as CT, DR, mammography, C-arm, CBCT, security inspection, industrial inspection, etc. The company has an advanced and efficient manufacturing platform with an annual production capacity of 50,000 units.
Novlead Biotech
Series A in 2021
Novlead Biotech is a developer and manufacturer of medical devices specializing in cardiopulmonary, respiratory, and anti-infection applications. The company leverages technological innovations, particularly the medical application of nitric oxide, to address conditions such as pulmonary hypertension and infectious diseases. By focusing on these critical areas, Novlead Biotech aims to enhance treatment efficiency in hospitals and improve the quality of life for patients. Through its advancements, the company contributes to safer and healthier outcomes in healthcare.
Applied Cells
Venture Round in 2021
Applied Cells, founded in 2017 and located in Santa Clara, California, specializes in innovative cell separation and enrichment products aimed at enhancing cancer treatment and diagnosis. The company develops advanced technologies that enable the isolation of rare cancer cells and the extraction of high-quality immune cells, improving the efficacy of cell therapies. By integrating novel immuno-separation, active-microfluidics, and fluidics control technologies, Applied Cells seeks to transform cellular sample preparation, allowing medical professionals and researchers to prepare high-efficiency samples essential for advancing cancer care.
Biobiggen
Venture Round in 2021
Biobiggen is a non-invasive prenatal chromosomal disease and monogenic disease simultaneous screening technology platform. It is focusing on the pregnancy and childbirth period, focusing on prenatal screening, supplemented by newborn screening and prenatal diagnosis, and deeply creating the most complete high-throughput prevention and control of genetic diseases and birth defects Sequencing technology series of innovative products, leading enterprises and unicorn enterprises in the subdivision field. The company is headquartered in Beijing Economic and Technological Development Zone, has an overseas research center in Houston, the United States, and an R&D transformation center, GMP production base, and medical testing laboratory in Beijing.
Genepoint Biological Technology
Venture Round in 2021
Genepoint Biological Technology (China) Co., Ltd. specializes in the manufacture of devices for cryogenic biomaterial storage and handling, aimed at supporting life sciences research. Based in Shanghai, the company offers a range of products, including Automated Cryo-Bio Storage systems, Plugged Hybrid Cryo-Storage units, and LIN Vapor Freezers. These innovative solutions are designed to facilitate biotechnology research and development by enhancing the efficiency of sample storage operations. Genepoint is committed to advancing cryogenic robotic systems, enabling researchers to manage biological samples effectively and conduct experiments with greater ease.
JAKA Biotech
Venture Round in 2021
JAKA Biotech is a manufacturer based in MinHang District, Shanghai, China, specializing in cosmetic functional raw materials. Founded in 2010, the company is dedicated to delivering effective skincare solutions through its expertise in plant extraction, fermentation, and synthesis. JAKA Biotech focuses on providing high-quality active ingredients that enhance skin beauty, utilizing advanced technology to create innovative raw materials for cosmetic production. Through its commitment to quality and efficacy, JAKA Biotech aims to meet the demands of clients in the cosmetic industry.
Diyi International Logistics
Venture Round in 2021
CNE invests in order to develop the sectors operational productivity, has developed an advanced integrated support service platform separately, and provides employment of automatic process sorting devices to attain an intelligent, efficient, and service company process. CNE has handled tens of thousands of cross-border e-commerce sellers and is the largest provider of inter-e-commerce logistics operations.
GiantMed Diagnostics
Venture Round in 2021
GiantMed Diagnostics is a third-party medical laboratory that specializes in the screening and diagnosis of complex eye diseases. Focused on precision ophthalmology, the company offers comprehensive testing services that include etiological testing, medical advice, medical consultations, and opportunities for scientific research collaboration. By providing a one-stop service for clinicians and patients, GiantMed Diagnostics aims to enhance the understanding and management of conditions such as uveitis and retinal choroidal diseases, thereby improving patient outcomes in the field of ophthalmology.
SaintSages
Venture Round in 2021
SaintSages is a minimally invasive energy device enterprise. The company is headquartered in Shanghai, China.
Viewtrix Technology
Series D in 2020
Viewtrix Technology specializes in the development of display driver chips and circuit boards, focusing on enhancing display resolution and color representation. The company's technologies support a variety of display types, including LCD, LED, and OLED, making them applicable to mobile phones, tablets, and notebooks. By providing these advanced solutions, Viewtrix Technology enables electronics manufacturers to improve the display quality of their products while also reducing costs.
Yunyinggu
Series D in 2020
Yunyinggu Technology Co., Ltd. is a Chinese start-up focused on the development and promotion of innovative display technologies aimed at enhancing the performance of flat panel displays. The company has created a proprietary solution recognized for achieving superior pixel density, or high pixels per inch (PPI), which can be utilized across various types of flat panels, including LCD, LED, and OLED displays. By advancing display technology, Yunyinggu seeks to contribute to the evolving landscape of visual performance in consumer electronics.
BSPK
Series A in 2020
BSPK, Inc. operates a digital platform aimed at enhancing the shopping experience for luxury brands and their clients. Founded in March 2017 and based in Menlo Park, California, the platform allows sales advisers to communicate directly with customers through various channels, including websites, in-store interactions, mobile devices, and video streaming. By providing access to product images and sales data, BSPK empowers luxury retail associates to create personalized connections with clients, ultimately improving client retention and driving sales. The company focuses on enabling luxury brands to manage client data effectively, thereby enhancing the overall client-brand experience.
BSPK
Series A in 2020
BSPK, Inc. operates a digital platform aimed at enhancing the shopping experience for luxury brands and their clients. Founded in March 2017 and based in Menlo Park, California, the platform allows sales advisers to communicate directly with customers through various channels, including websites, in-store interactions, mobile devices, and video streaming. By providing access to product images and sales data, BSPK empowers luxury retail associates to create personalized connections with clients, ultimately improving client retention and driving sales. The company focuses on enabling luxury brands to manage client data effectively, thereby enhancing the overall client-brand experience.
Kasa
Series A in 2020
Kasa Korea Co., Ltd. is a company based in Seoul, South Korea, that specializes in developing a digital securities blockchain platform tailored for the real estate market. Established in 2018, Kasa's platform enables users to buy and trade securitized commercial real estate assets as asset-backed securities. By leveraging blockchain technology, the company aims to provide retail investors with a transparent and streamlined process for investing in real estate, facilitating the buying and selling of securitized assets in a more efficient manner.
Tensor Security
Angel Round in 2020
Tensor Security is a full-stack endogenous cloud-native security solution. Their solution includes automation and devsecops,safety compliance, market container security,dynamic privileged account management, and cloud host security. Their cloud-native security platform builds a trusted image security system to ensure image security throughout the entire life cycle of cloud-native applications.
Hugo Biotech
Series A in 2020
Hugo Biotech is a developer of advanced microbial sequencing technology, specializing in high-throughput sequencing and genomic analysis. The company has sequenced nearly 20,000 clinical samples for over 300 leading hospitals in China. Its innovative approach allows for the rapid and precise identification of pathogenic microorganisms in clinical samples, eliminating the need for traditional culturing methods and specific amplification techniques. This capability supports healthcare professionals in making timely and informed decisions regarding patient treatment.
BrosMed
Series C in 2020
BrosMed is a company that specializes in interventional vascular therapy services and the development of medical devices aimed at enhancing procedural outcomes for healthcare professionals. The company's product offerings include a series of interventional cardiovascular and endovascular catheters, which are utilized by cardiologists, radiologists, and vascular surgeons during angioplasty procedures and other minimally invasive interventions. By providing advanced medical devices, BrosMed enables clinicians to expand treatment options available to patients, ultimately contributing to improved patient outcomes while also reducing costs.
Reworld
Series B in 2020
Reworld is a platform offering training and IT tools that allow users to design their own videogames.
MemVerge
Series B in 2020
MemVerge specializes in memory storage convergence software that integrates memory and storage to enhance data processing capabilities. The company's innovative platform utilizes proprietary Distributed Memory Objects (DMO) technology, creating a logical convergence layer that leverages Intel's Optane DC persistent memory. This technology allows data-intensive workloads, including artificial intelligence, machine learning, big data analytics, and IoT applications, to operate at memory speed, ensuring data consistency across various systems. By enabling enterprises to manage both small and large files efficiently, MemVerge empowers organizations to extract insights from their data more effectively.
TenaFe
Series A in 2020
TenaFe, Inc. is a technology company that specializes in the development of solid-state drive (SSD) controllers aimed at enhancing data storage solutions across various platforms, including client devices, data centers, and emerging edge applications. Founded in 2018 and based in Campbell, California, TenaFe leverages its patented technology to deliver SSDs characterized by exceptional reliability, performance, and energy efficiency. These innovations serve a diverse array of devices, from connected gadgets and personal computers to large-scale data center operations, ultimately improving storage reliability and energy consumption for its clients.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.